Virbac Stock Rebounds by 2% and Attempts to Exit Oversold Territory
Mid-morning, the veterinary laboratory in Carros shows signs of recovery in a slightly bullish Parisian market. The stock rebounds after several sessions of consolidation that had brought it to a closely watched technical threshold. The RSI indicates seller exhaustion which this rebound is starting to correct.
A Technical Rebound Moving Away from the €329.50 Support
Virbac stock gains 2.12% to €336.50 during the session, after testing its support at €332 the previous day. The stock rebounds from the €329.50 zone, a floor identified where buyers are regaining control. The movement occurs in a supportive index context, with the SBF 120 up by 0.23% at the same time. However, the rebound remains limited compared to the accumulated decline: the stock is still down 1.75% for the week and nearly 4.7% over three months.
The RSI at 34, close to the oversold zone, reflects the exhaustion of sellers after the downward phase that had caused the price to break through its moving averages. The stock remains below its MM20 (€348.58), MM50 (€357.54), and MM200 (€349.11), with a gap of 3.47% to 5.88% depending on the horizon. Reclaiming the MM20 would be the next technical step observable to confirm the turnaround initiated.
Target Raised by TP ICAP and General Meeting Scheduled for Late June
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The analysis context remains favorable since last month. On May 21, TP ICAP had raised its price target to €412 for the stock, while it was trading at €369. At the current price of €336.50, this target represents a gap of around 22%. The analysts' opinion thus remains positive, despite the consolidation of recent weeks.
On the calendar, the next event is the annual ordinary general meeting, scheduled for June 26. The veterinary laboratory, headquartered in Carros (Alpes-Maritimes) and chaired by Marie-Hélène Dick, has not communicated any specific news for the session. The underlying trend remains bearish over a month (-2.61%), but the stock maintains a positive performance over a year (+5.49%). The return to the MM20 at €348.58 will be the next technical marker to watch.
SectorPharmacie et biotechnologies›Pharmacie, vaccins et santé animale
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 1 168 millions d'euros
Quarterly revenue: 1 168 millions d'euros
Guidance from the release
Notre solide performance à fin septembre 2026 nous permet de viser le haut de notre fourchette initiale de croissance du chiffre d'affaires
Risks mentioned
Effets de change défavorables impactant la croissance réelle (croissance réelle +5,9% vs +7,9% à taux constants)
Pression concurrentielle persistante sur les vaccins porcins en Asie de l'Est et pressions tarifaires au segment Animaux d'élevage
Exposition au Moyen-Orient et suivi des tendances inflationnistes (énergie) malgré anticipation d'impacts limités
Opportunities identified
Croissance soutenue des plateformes Supercharge (+11% environ) couvrant petfood, reproduction, dentaire, mobilité, otologie, endocrinologie et ruminants
Intégration fluide de Thyronorm dans la franchise d'endocrinologie avec contribution de +1 point de croissance et +0,5 point d'Ebit ajusté
Redémarrage réussi de la production du contrat majeur de façonnage en Amérique du Nord (juillet 2026) après contrainte réglementaire temporaire
Outlook / guidance
Expected revenue: 1 575 millions d'euros
Management commentary: « Bien que nos perspectives pour l'ensemble de l'année 2026 restent inchangées, notre solide performance à fin septembre (croissance de +7,9%) nous permet de viser la borne haute de notre fourchette de croissance du chiffre d'affaires de 5,5 % à 7,5 % à PCC »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
